Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

By /

With Elevidys expansion in hand, Sarepta commits up to $10 billion to develop short interfering RNA–based drugs to build out its pipeline.

Scroll to Top